8-K: Aquestive Therapeutics Extends RTW Deal, Addresses FDA Anaphylm CRL

Aquestive Therapeutics reported Q4 and full-year 2025 financial results, extended its revenue sharing agreement with RTW, and outlined a plan to address the FDA's Complete Response Letter for Anaphylm.

Summary

• Received a Complete Response Letter (CRL) from the FDA for the Anaphylm NDA on January 30, 2026, citing human factors validation deficiencies related to pouch opening and film placement, and requesting a single pharmacokinetics (PK) study.
• The CRL did not identify any chemistry, manufacturing, or controls (CMC) deficiencies, nor did it question clinical results regarding comparability to auto-injectors.
• NDA resubmission for Anaphylm is anticipated in the third quarter of 2026, subject to completion of the required human factors validation and PK studies.
• Extended the Marketing Approval Deadline for Anaphylm with funds managed by RTW Investments, LP to June 30, 2027.
• Issued a warrant to RTW funds to purchase up to 375,000 shares of common stock at an exercise price of $4.00 per share, expiring on March 3, 2029.
• RTW-affiliated funds committed to purchase, in the aggregate, not less than $5,000,000 of Common Stock during the 90-day period following March 3, 2026.
• Reported Q4 2025 total revenues of $13.0 million, a 10% increase from Q4 2024, primarily driven by manufacture and supply revenue.
• Reported a Q4 2025 net loss of $31.9 million, or $0.26 per share, including approximately $13.6 million in one-time legal expenses.
• Full-year 2025 total revenues were $44.5 million, a decrease from $57.6 million in FY 2024 (or a 3% decrease excluding one-time deferred revenue recognition in 2024).
• Full-year 2025 net loss was $83.8 million, or $0.78 per share, including approximately $14.3 million in one-time legal expenses.
• Ended 2025 with $121.2 million in cash and cash equivalents.
• Provided 2026 guidance: total revenue of $46 million to $50 million and non-GAAP adjusted EBITDA loss of $35 million to $30 million.
• Successfully opened an Investigational New Drug (IND) application for AQST-108 (topical epinephrine prodrug gel) in Q4 2025 and completed dosing in a second Phase 1 clinical trial in Q1 2026, with data readout expected in Q2 2026.
• Entered into a confidential legal settlement with Neurelis, Inc. in December 2025, expecting the 2026 cash impact to be the same as or lower than forecasted.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed filing. While the FDA CRL for Anaphylm is a significant setback and delays a key product, the nature of the deficiencies (human factors, packaging) appears addressable, and the financial agreements with RTW provide capital and continued support. The increased net loss is concerning, but the cash position and pipeline progress offer some resilience.

Positives

• Q4 2025 total revenues increased by 10% to $13.0 million, primarily driven by increases in manufacture and supply revenue.
• Ended 2025 with a strong cash and cash equivalents balance of $121.2 million, providing a projected cash runway into 2027.
• The Marketing Approval Deadline for Anaphylm with RTW was extended to June 30, 2027, indicating continued partner support and flexibility.
• RTW-affiliated funds committed to purchase at least $5,000,000 of Common Stock, strengthening the company's financial position.
• The FDA's CRL for Anaphylm did not identify any CMC deficiencies or question clinical results regarding comparability to auto-injectors, suggesting the core therapeutic profile is sound.
• No additional studies beyond the requested human factors validation study and related PK study were identified for Anaphylm, providing a clear path forward.
• Successfully opened an IND for AQST-108 and completed dosing in a Phase 1 clinical trial, advancing the AdrenaVerse platform for potential dermatological indications like alopecia areata.
• AQST-108, if approved, has the potential to capture meaningful market share in the over $1 billion alopecia areata market due to its topical nature and potential for fewer systemic side effects compared to existing JAK inhibitors.
• Manufacturing operations continue to generate cash, with approximately 47 million doses manufactured in Q4 2025, an increase from 43 million doses in Q4 2024.
• The company's supply chain remains largely unaffected by government tariffs, providing continued reliability and stability in production and global distribution.
• A confidential legal settlement with Neurelis, Inc. in December 2025 is expected to have a cash impact in 2026 that is the same as or lower than previously forecasted.

Negatives

• Received a Complete Response Letter (CRL) from the FDA for Anaphylm, delaying its potential approval and commercial launch.
• Q4 2025 net loss increased significantly to $31.9 million from $17.1 million in Q4 2024, primarily due to approximately $13.6 million in one-time legal expenses and higher commercial spending.
• Full-year 2025 net loss increased substantially to $83.8 million from $44.1 million in FY 2024, driven by higher selling, general and administrative expenses, including $14.3 million in one-time legal expenses.
• Non-GAAP adjusted EBITDA loss widened in both Q4 2025 ($14.1 million) and full-year 2025 ($49.7 million) compared to prior periods.
• Libervant (diazepam) Buccal Film remains tentatively approved until January 2027 due to existing orphan drug market exclusivity of a competitor's product, delaying full U.S. market access.
• The CRL for Anaphylm requires additional human factors validation and a PK study, which will incur further costs and time.
• The 2026 guidance projects another year of non-GAAP adjusted EBITDA loss, ranging from $35 million to $30 million.

Risks

• Delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm and AQST-108.
• Risk of delays in the regulatory approval process through the FDA for Anaphylm, Libervant, and AQST-108, or failure to receive FDA approval at all.
• Risk of FDA inspections of manufacturing and clinical study sites for any product candidates.
• Risk of government shutdowns or actions to reduce government workforces impacting the FDA's ability to act on product approvals.
• Risk of the company's ability to generate sufficient clinical and other human factor data, including pharmacokinetic and pharmacodynamic (PK/PD) comparability data for Anaphylm.
• Risks associated with the ability to address the FDA's comments and identified deficiencies in the Anaphylm NDA, including potential requests for further information or additional clinical studies.
• Challenges regarding the commercial launch of Anaphylm, if approved by the FDA.
• Risks associated with the success of any competing products, including generics.
• Uncertainties inherent in commercializing a new product, including technology, financial, market, implementation risks, and regulatory limitations.
• Risk of developing a sales and marketing capability for commercialization of product candidates.
• Risk of insufficient capital and cash resources, including access to debt and equity financing, to satisfy short-term and longer-term liquidity and cash requirements, and to fund future clinical development and commercial activities.
• Impact of obligations under the Purchase Agreement and Royalty Rights Agreement on the ability to fund operations and make debt payments, and potential impact on refinancing 13.5% Senior Secured Notes.
• Risk that manufacturing capabilities will be insufficient to support demand of product candidates.
• Risk of eroding market share for Suboxone as a sunsetting product, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to the outsourcing of certain sales, marketing, and other operational and staff functions to third parties.
• Risk of the rate and degree of market acceptance in the U.S. and abroad of product candidates.
• Risk associated with compliance with all FDA and other governmental and customer requirements for manufacturing facilities.
• Risks associated with intellectual property rights and infringement claims relating to products, including timely issuance of patents and their sufficiency for long-term commercial success.
• Risk of unexpected patent developments.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business, including product pricing, reimbursement, or access.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to any disruptions in information technology networks and systems, including the impact of cybersecurity attacks.
• Risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements.
• Risk of adverse developments affecting the financial services industry.
• Risks related to inflation and changing interest rates.
• Risks related to the impact of pandemic diseases on the business.
• Risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial, and market conditions and other unusual items.
• Risks related to uncertainty about presidential administration initiatives and their impact on the business, including imposition of government tariffs and other trade restrictions.

Future Outlook

Aquestive Therapeutics anticipates resubmitting the Anaphylm NDA in the third quarter of 2026, following the completion of required human factors validation and PK studies. The company expects full-year 2026 total revenues to be between $46 million and $50 million, with a non-GAAP adjusted EBITDA loss projected between $35 million and $30 million. This guidance includes costs for Anaphylm resubmission, continued pre-commercial spending for Anaphylm, clinical trials for AQST-108, and regulatory applications for Anaphylm in Canada and the EU, but excludes costs associated with the sales and marketing of Anaphylm, if approved by the FDA.

Management Comments

• "We are well-positioned in 2026 to advance Anaphylm, the first and only oral epinephrine rescue medication, towards approval for patients around the world." Daniel Barber, President and Chief Executive Officer.
• "We continue to believe the value proposition will be transformative and ultimately save lives." Daniel Barber, President and Chief Executive Officer.
• "We are focused on rapidly addressing the human factors focused deficiencies cited by the FDA in their recent Complete Response Letter." Daniel Barber, President and Chief Executive Officer.
• "We've never been more confident in Anaphylm's potential to make a meaningful difference for the allergy community." Daniel Barber, President and Chief Executive Officer.

Industry Context

StockSavvy.ai notes that the delay in Anaphylm's FDA approval, while a setback, is focused on human factors and packaging, not the core clinical efficacy or manufacturing. This suggests the underlying drug candidate remains promising in a growing allergy market where patient preference for non-invasive options is strong. The advancement of AQST-108 into Phase 1 for alopecia areata positions Aquestive to potentially disrupt a multi-billion dollar market currently dominated by systemic JAK inhibitors with significant side effects, offering a topical alternative. The continued manufacturing collaborations provide a stable revenue base amidst pipeline development.

Comparison to Industry Standards

• Anaphylm's clinical results regarding comparability to auto-injectors such as EpiPen and Auvi-Q were not questioned by the FDA, suggesting its therapeutic profile is competitive with established emergency epinephrine products.
• AQST-108 for alopecia areata aims to compete with existing janus kinase (JAK) inhibitors, which are systemic treatments with 'black box' warnings and high costs, representing an estimated market opportunity over $1 billion. AQST-108's topical formulation and potential for localized action without systemic side effects could offer a significant advantage over these current standards.
• Libervant is positioned as an alternative to device-based products for acute repetitive seizures, including rectal gel and nasal spray products, aiming to expand patient access to non-invasive seizure rescue therapies.

Management Changes

Legal Proceedings

• Aquestive Therapeutics entered into a confidential legal settlement with Neurelis, Inc. in December 2025, related to a civil tort case filed by Neurelis, Inc. in December 2019.
• The cash impact of this settlement in 2026 is expected to be the same as or lower than forecasted prior to the settlement, net of insurance payments and reduced ongoing legal costs.

Related Party Transactions

• Amendment No. 1 to the Purchase and Sale Agreement, dated August 13, 2025, was entered into with funds managed by RTW Investments, LP, extending the Marketing Approval Deadline for Anaphylm to June 30, 2027.
• A Warrant Issuance Agreement was entered into with funds managed by RTW, pursuant to which the company agreed to issue a warrant to purchase up to 375,000 shares of common stock at an exercise price of $4.00 per share, expiring March 3, 2029.
• A Share Purchase Commitment Agreement was entered into with certain RTW-affiliated funds, committing them to purchase, in the aggregate, not less than $5,000,000 of Common Stock during the 90-day period following March 3, 2026.

Stakeholder Impact

• Shareholders face potential dilution from the warrant exercise and share purchase commitment, and the delay in Anaphylm approval could impact stock price and future revenue. However, continued support from RTW and a strong cash position provide some stability.
• Patients awaiting Anaphylm will experience delayed access to a potentially transformative non-invasive epinephrine product, though the company remains committed to bringing it to market.
• Patients awaiting Libervant will continue to experience delays in full U.S. market access due to existing orphan drug exclusivity.
• Patients with alopecia areata may benefit in the future from AQST-108, a topical treatment with potentially fewer systemic side effects than current options.
• Employees involved in Anaphylm development and launch preparation may see continued stability in their roles as the company addresses FDA requirements and prepares for future commercialization.
• Creditors may view the company's cash position and new financial agreements with RTW as positive indicators for managing debt obligations, including principal payments on 13.5% Senior Secured Notes in 2026.

Next Steps

• Request a Type A meeting with the FDA to discuss the most efficient path forward for Anaphylm resubmission.
• Conduct a new human factors validation study for Anaphylm to address identified deficiencies.
• Conduct a single pharmacokinetics (PK) study for Anaphylm to assess the impact of packaging and labeling modifications.
• Resubmit the Anaphylm NDA in the third quarter of 2026.
• Request an accelerated review for Anaphylm upon resubmission.
• Advance global expansion strategy for Anaphylm, including ongoing regulatory engagement in Canada and preparatory activities in the European Union.
• Continue to prepare for the launch of Anaphylm, if approved, focusing on market access and medical affairs strategy.
• Expect data readout from the second Phase 1 clinical trial for AQST-108 in the second quarter of 2026.
• RTW-affiliated funds are committed to purchase at least $5,000,000 of Common Stock during the 90-day period following March 3, 2026.
• Host an investment community conference call on March 5, 2026.

Key Dates

Recommendation

The FDA's Complete Response Letter for Anaphylm is a significant setback, introducing delays and additional costs, which typically warrants a negative market reaction. However, the nature of the deficiencies appears addressable, and the company has secured additional financial commitments from RTW, providing liquidity and continued partner confidence. The strong cash position and progress on other pipeline assets like AQST-108 offer some mitigating factors. Given the uncertainty around the Anaphylm resubmission timeline and outcome, alongside the financial burn, a 'hold' recommendation is appropriate as investors await clearer regulatory and commercial pathways.

Keywords

Aquestive Therapeutics, AQST, Anaphylm, dibutepinephrine, sublingual film, epinephrine, anaphylaxis, FDA CRL, human factors validation, PK study, NDA resubmission, AQST-108, topical gel, alopecia areata, AdrenaVerse, RTW Investments, warrant, share purchase commitment, financial results, Q4 2025, FY 2025, 2026 outlook, Libervant, diazepam buccal film, seizure clusters, pharmaceutical, biotech, drug development, regulatory approval, corporate finance